QDEL: Dislocated Diagnostics — A Value Bet If 2026 FCF Materializes
QuidelOrtho (QDEL) trades like a distressed name but carries assets, market exposure to growing point-of-care diagnostics, and an EV/EBITDA of ~6.7. If management's 2026 free-cash-flow turnaround proves real, the stock can re-rate meaningfully. This is a structured, long-biased trade for patient, event-driven investors.